Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

Home

/

VYGR

V

Voyager Therapeutics, Inc. (VYGR)

NMS – Цена в реальном времени. Валюта: USD

4.15

+0.03 (0.73%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.53 per share a year ago.

Voyager Reports First Quarter 2026 Financial and Operating Results

Voyager Reports First Quarter 2026 Financial and Operating Results

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended Q1 2026 with cash position of $172 million, runway into 2028 - LEXINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported first quarter 2026 financial and operating results.

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease

- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs -

Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026

Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026

Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients. Company's robust cash position, projected to fund operations into 2028, is further supported by potential $2.4B in milestone payments and ongoing collaborations.

Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript

Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript

Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript

Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates

Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.59 per share a year ago.

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 - LEXINGTON, Mass.

Видео

No Data

There is no data to display

Пресс-релизы

Voyager Reports First Quarter 2026 Financial and Operating Results

Voyager Reports First Quarter 2026 Financial and Operating Results

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended Q1 2026 with cash position of $172 million, runway into 2028 - LEXINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported first quarter 2026 financial and operating results.

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease

- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs -

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 - LEXINGTON, Mass.

Voyager Reports Third Quarter 2025 Financial and Operating Results

Voyager Reports Third Quarter 2025 Financial and Operating Results

- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 - LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2025 financial and operating results.